Overview

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA). It is hypothesized that administration of XOMA 052 is likely to improve inflammatory control in subjects with RA.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC